Identification of Lysine Succinylation Substrates and the Succinylation Regulatory Enzyme CobB in Escherichia coli

Lysine succinylation is a newly identified protein post-translational modification pathway present in both prokaryotic and eukaryotic cells. However, succinylation substrates and regulatory enzyme(s) remain largely unknown, hindering the biological study of this modification. Here we report the identification of 2,580 bacterial lysine succinylation sites in 670 proteins and 2,803 lysine acetylation (Kac) sites in 782 proteins, representing the first lysine succinylation dataset and the largest Kac dataset in wild-type E. coli. We quantified dynamic changes of the lysine succinylation and Kac substrates in response to high glucose. Our data showed that high-glucose conditions led to more lysine-succinylated proteins and enhanced the abundance of succinyllysine peptides more significantly than Kac peptides, suggesting that glucose has a more profound effect on succinylation than on acetylation. We further identified CobB, a known Sir2-like bacterial lysine deacetylase, as the first prokaryotic desuccinylation enzyme. The identification of bacterial CobB as a bifunctional enzyme with lysine desuccinylation and deacetylation activities suggests that the eukaryotic Kac-regulatory enzymes may have enzymatic activities on various lysine acylations with very different structures. In addition, it is highly likely that lysine succinylation could have unique and more profound regulatory roles in cellular metabolism relative to lysine acetylation under some physiological conditions.Lysine acetylation (Kac)¹ is a dynamic and evolutionarily conserved post-translational modification (PTM) that is known to be involved in the regulation of diverse cellular processes (1–9). The status of this modification is controlled by two groups of enzymes with opposing enzymatic activities, lysine acetyltransferases that add an acetyl group to the lysine (Lys or K) residue, and histone lysine deacetylases (HDACs) that remove the acetyl group (10–16). HDACs are grouped into several categories (17): class I (HDAC1, -2, -3, and -8), class IIA (HDAC4, -5, -7, and -9), class IIB (HDAC6 and -10), class III (Sirt1–7), and class IV (HDAC11). The weak deacetylation activities of some HDACs (e.g. Sirt4–7 and HDAC4, -5, and -7–11), as well as the demonstration of Sirt5 as a desuccinylation and demalonylation enzyme, suggest that some HDAC enzymes have activities that are independent of acetylation (18, 19).For a long period of time, lysine acetylation was considered as a protein modification that was restricted to nuclei (20). The identification of cytosolic Kac substrates and the localization of some HDACs outside nuclei suggest a non-nuclear function of lysine acetylation (13, 21, 22). The first proteomic screening identified hundreds of substrate proteins in cytosolic and mitochondrial fractions and demonstrated high abundance of Kac in mitochondrial proteins and metabolic enzymes (23). This result implies that Kac has diverse non-nuclear roles and can regulate functions of metabolism and mitochondria (23). Since then, we and others have extensively characterized the cellular acetylome (5, 9, 24–26).The lysine succinylation (Ksucc) and lysine malonylation pathways are two PTM pathways that were recently identified and comprehensively validated in both bacterial and mammalian cells, with multiple substrate proteins identified, using HPLC-MS/MS, co-elution of synthetic peptides, isotopic labeling, Western blotting analysis using pan-anti-Ksucc antibodies, and proteomics analysis (18, 27). We also showed that Ksucc is present in core histones (29). In yeast histones, some Ksucc sites are located in regions where histones make close contact with DNA, suggesting that Ksucc sites may be involved in gene regulation by changing the chromatin structure (29). We then found that Sirt5, a member of the class III family of HDACs, can function as a desuccinylation enzyme in vitro and in vivo (18, 19). In a recent study, we revealed that Sirt5 is a key regulatory enzyme of Ksucc and that Ksucc proteins are abundant among a group of mitochondrial enzymes that are predominantly involved in fatty acid metabolism, amino acid degradation, and the tricarboxylic acid cycle (28). Importantly, Ksucc is very dynamic not only in mammalian cells, but also in bacteria (27, 29). These lines of evidence strongly suggest that lysine succinylation is likely an important PTM in the regulation of cellular functions.Although key elements of the Ksucc pathway are being identified in mammalian cells, their counterparts in bacteria remain largely unknown. We and others have used a proteomics approach to identify Kac substrates in bacteria (26, 30, 31, 52). The Sir2-like enzyme CobB is the best-studied protein deacetylase in bacteria (8). CobB was initially identified as an enzyme required for the activation of acetyl-CoA synthetase (8). Recently, CobB was shown to play roles in bacterial energy metabolism (31) and stress response (32). Those studies indicated that Kac is an evolutionarily conserved PTM with a role in energy metabolism in prokaryotes. Nevertheless, dynamic changes of lysine acetylation in bacteria have not been studied. In addition, substrates of lysine succinylation and their regulatory enzymes are not known.In this paper, we report a quantitative proteomic approach based on stable isotope labeling by amino acids in cell culture (SILAC) to identify and quantify changes in bacterial lysine succinylation, as well as lysine acetylation, in response to glucose, a major energy source. Our screening detected 2,580 lysine-succinylated sites in 670 proteins and 2,803 Kac sites in 782 proteins in Escherichia coli. Our quantitative proteomics data show that glucose had a more profound effect on Ksucc than on Kac. In addition, we found that CobB, a known prokaryotic deacetylase, had dual enzymatic activities to catalyze the removal of two structurally different lysine acyl groups, acetyl and succinyl, from the modified lysine residues.     

Proinsulin and the Genetics of Diabetes Mellitus

Insulin plays a central role in the regulation of vertebrate metabolism. The hormone, the post-translational product of a single-chain precursor, is a globular protein containing two chains, A (21 residues) and B (30 residues). Recent advances in human genetics have identified dominant mutations in the insulin gene causing permanent neonatal-onset DM² (1–4). The mutations are predicted to block folding of the precursor in the ER of pancreatic β-cells. Although expression of the wild-type allele would in other circumstances be sufficient to maintain homeostasis, studies of a corresponding mouse model (5–7) suggest that the misfolded variant perturbs wild-type biosynthesis (8, 9). Impaired β-cell secretion is associated with ER stress, distorted organelle architecture, and cell death (10). These findings have renewed interest in insulin biosynthesis (11–13) and the structural basis of disulfide pairing (14–19). Protein evolution is constrained not only by structure and function but also by susceptibility to toxic misfolding.Insulin plays a central role in the regulation of vertebrate metabolism. The hormone, the post-translational product of a single-chain precursor, is a globular protein containing two chains, A (21 residues) and B (30 residues). Recent advances in human genetics have identified dominant mutations in the insulin gene causing permanent neonatal-onset DM² (1–4). The mutations are predicted to block folding of the precursor in the ER of pancreatic β-cells. Although expression of the wild-type allele would in other circumstances be sufficient to maintain homeostasis, studies of a corresponding mouse model (5–7) suggest that the misfolded variant perturbs wild-type biosynthesis (8, 9). Impaired β-cell secretion is associated with ER stress, distorted organelle architecture, and cell death (10). These findings have renewed interest in insulin biosynthesis (11–13) and the structural basis of disulfide pairing (14–19). Protein evolution is constrained not only by structure and function but also by susceptibility to toxic misfolding.     

Printor, a Novel TorsinA-interacting Protein Implicated in Dystonia Pathogenesis

Early onset generalized dystonia (DYT1) is an autosomal dominant neurological disorder caused by deletion of a single glutamate residue (torsinA ΔE) in the C-terminal region of the AAA⁺ (ATPases associated with a variety of cellular activities) protein torsinA. The pathogenic mechanism by which torsinA ΔE mutation leads to dystonia remains unknown. Here we report the identification and characterization of a 628-amino acid novel protein, printor, that interacts with torsinA. Printor co-distributes with torsinA in multiple brain regions and co-localizes with torsinA in the endoplasmic reticulum. Interestingly, printor selectively binds to the ATP-free form but not to the ATP-bound form of torsinA, supporting a role for printor as a cofactor rather than a substrate of torsinA. The interaction of printor with torsinA is completely abolished by the dystonia-associated torsinA ΔE mutation. Our findings suggest that printor is a new component of the DYT1 pathogenic pathway and provide a potential molecular target for therapeutic intervention in dystonia.Early onset generalized torsion dystonia (DYT1) is the most common and severe form of hereditary dystonia, a movement disorder characterized by involuntary movements and sustained muscle spasms (1). This autosomal dominant disease has childhood onset and its dystonic symptoms are thought to result from neuronal dysfunction rather than neurodegeneration (2, 3). Most DYT1 cases are caused by deletion of a single glutamate residue at positions 302 or 303 (torsinA ΔE) of the 332-amino acid protein torsinA (4). In addition, a different torsinA mutation that deletes amino acids Phe³²³–Tyr³²⁸ (torsinA Δ323–328) was identified in a single family with dystonia (5), although the pathogenic significance of this torsinA mutation is unclear because these patients contain a concomitant mutation in another dystonia-related protein, ϵ-sarcoglycan (6). Recently, genetic association studies have implicated polymorphisms in the torsinA gene as a genetic risk factor in the development of adult-onset idiopathic dystonia (7, 8).TorsinA contains an N-terminal endoplasmic reticulum (ER)³ signal sequence and a 20-amino acid hydrophobic region followed by a conserved AAA⁺ (ATPases associated with a variety of cellular activities) domain (9, 10). Because members of the AAA⁺ family are known to facilitate conformational changes in target proteins (11, 12), it has been proposed that torsinA may function as a molecular chaperone (13, 14). TorsinA is widely expressed in brain and multiple other tissues (15) and is primarily associated with the ER and nuclear envelope (NE) compartments in cells (16–20). TorsinA is believed to mainly reside in the lumen of the ER and NE (17–19) and has been shown to bind lamina-associated polypeptide 1 (LAP1) (21), lumenal domain-like LAP1 (LULL1) (21), and nesprins (22). In addition, recent evidence indicates that a significant pool of torsinA exhibits a topology in which the AAA⁺ domain faces the cytoplasm (20). In support of this topology, torsinA is found in the cytoplasm, neuronal processes, and synaptic terminals (2, 3, 15, 23–26) and has been shown to bind cytosolic proteins snapin (27) and kinesin light chain 1 (20). TorsinA has been proposed to play a role in several cellular processes, including dopaminergic neurotransmission (28–31), NE organization and dynamics (17, 22, 32), and protein trafficking (27, 33). However, the precise biological function of torsinA and its regulation remain unknown.To gain insights into torsinA function, we performed yeast two-hybrid screens to search for torsinA-interacting proteins in the brain. We report here the isolation and characterization of a novel protein named printor (protein interactor of torsinA) that interacts selectively with wild-type (WT) torsinA but not the dystonia-associated torsinA ΔE mutant. Our data suggest that printor may serve as a cofactor of torsinA and provide a new molecular target for understanding and treating dystonia.     

Tubacin Kills Epstein-Barr Virus (EBV)-Burkitt Lymphoma Cells by Inducing Reactive Oxygen Species and EBV Lymphoblastoid Cells by Inducing Apoptosis

Tubacin is a small molecule inhibitor of histone deacetylase 6 and blocks aggresome activity. We found that Epstein-Barr virus (EBV)-positive Burkitt lymphoma (BL) cells were generally killed by lower doses of tubacin than EBV-transformed lymphoblastoid cells (LCLs) or EBV-negative BL cells. Tubacin induced apoptosis of LCLs, which was inhibited by pretreatment with a pancaspase inhibitor but not by butylated hydroxyanisole, which inhibits reactive oxygen species. In contrast, tubacin killed EBV-positive BL cells in a caspase-3-independent pathway that involved reactive oxygen species and was blocked by butylated hydroxyanisole. Previously, we showed that bortezomib, a proteasome inhibitor, induces apoptosis of EBV LCLs and that LCLs are killed by lower doses of bortezomib than EBV-positive BL cells. Here we found that the combination of bortezomib and tubacin acted in synergy to kill EBV-positive BL cells and LCLs. Tubacin or the combination of bortezomib and tubacin did not induce EBV lytic replication. These findings suggest that the combination of a proteasome inhibitor and an HDAC6 inhibitor may represent a useful strategy for the treatment of certain EBV-associated B cell lymphomas.Epstein-Barr virus (EBV)⁴ is associated with several human lymphoid malignancies, including Hodgkin disease, Burkitt lymphoma (BL), T cell lymphomas, and post-transplant lymphoproliferative disease (1, 2). Tissues from patients with EBV post-transplant lymphoproliferative disease typically have a type 3 latency pattern in which each of the EBV latency-associated proteins, including EBV nuclear antigens (EBNA-1, -2, -3A, -3B, and -3C) and latent membrane proteins (LMP1 and LMP2) are expressed. A type 3 latency pattern is also seen in lymphoblastoid cell lines (LCLs), derived from primary B cells transformed with EBV in vitro. Tissues from patients with EBV-positive BL usually have a type 1 latency pattern with expression of EBNA-1 but not the other latency-associated proteins. When grown in cell culture, BL cell lines can have a type 1 or a type 3 pattern of latency.The treatment of EBV-associated lymphoid malignancies often requires cytotoxic chemotherapy, which is not always successful. Inhibition of proteasomes and aggresomes represents new therapeutic targets for malignancies (3–5). Degradation of proteins is required for vital cell functions and is carried out both in proteasomes and aggresomes. Misfolded or unfolded proteins are polyubiquitinated by a complex of proteins and subsequently degraded by proteasomes. However, if ubiquitinated proteins escape degradation by proteasomes and aggregate, they accumulate into aggresomes (6). Aggresome formation can be abrogated by disrupting the microtubule cytoskeleton or by overexpression of the p50 subunit of dynactin (7). HDAC6 (histone deacetylase 6) is a microtubule-associated deacetylase that can induce microtubule disassembly and promote chemotactic cell motility (8–10). HDAC6 contains a dynein motor binding domain, two catalytic domains with histone deacetylase activity, and a carboxyl-terminal domain that binds polyubiquitinated misfolded proteins (11). The carboxyl catalytic domain of HDAC6 possesses α-tubulin deacetylase activity (12). HDAC6 is required for transport of misfolded proteins for aggresome formation and to prevent apoptosis in response to misfolded protein stress (11). HDAC6 inhibitors disrupt aggresomes (5). Tubacin inhibits the carboxyl catalytic domain of HDAC6, increases the level of acetylated α-tubulin, and blocks aggresome activity (4, 12, 13).Bortezomib is an inhibitor of the 26 S proteasome (3). Previously, we showed that bortezomib induces apoptosis of EBV-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells (14). In contrast, EBV-negative Burkitt lymphoma cells were much less sensitive to killing by bortezomib. Since bortezomib has been shown to interact synergistically with tubacin to induce apoptosis in multiple myeloma cells (4), we studied the effect of tubacin on EBV-transformed B cells and Burkitt lymphoma cells both in the absence and presence of bortezomib. We show that tubacin kills LCLs by apoptosis and induction of caspase-3, whereas tubacin kills EBV-positive BL cells by induction of reactive oxygen species. Bortezomib and tubacin acted in synergy to kill EBV-positive BL cells and LCLs. These findings suggest that the combination of tubacin and bortezomib may have potential as a model for the treatment of certain EBV-associated lymphomas.